M
Maurice P.H.M. Jansen
Researcher at Erasmus University Rotterdam
Publications - 60
Citations - 2343
Maurice P.H.M. Jansen is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 20, co-authored 49 publications receiving 2025 citations. Previous affiliations of Maurice P.H.M. Jansen include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
Sherene Loi,Benjamin Haibe-Kains,Christine Desmedt,Pratyaksha Wirapati,Françoise Lallemand,Andrew Tutt,Cheryl Gillet,Paul Ellis,Kenneth Ryder,James F. Reid,Maria Grazia Daidone,M. A. Pierotti,Els M.J.J. Berns,Maurice P.H.M. Jansen,John A. Foekens,Mauro Delorenzi,Gianluca Bontempi,Martine Piccart,Christos Sotiriou +18 more
TL;DR: A gene classifier that can predict clinical outcome in tamoxifen-treated ER+ BC patients is developed and other genes and pathways that may elucidate further mechanisms that influence clinical outcome and prediction of response to tamoxIFen are proposed.
Journal ArticleDOI
Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling
Maurice P.H.M. Jansen,John A. Foekens,Iris L. van Staveren,Maaike J.M. Dirkzwager-Kiel,Kirsten Ritstier,Maxime P. Look,Marion E. Meijer-van Gelder,Anieta M. Sieuwerts,H. Portengen,Lambert C. J. Dorssers,Jan G. M. Klijn,Els M.J.J. Berns +11 more
TL;DR: Data show that gene expression profiling can be used to discriminate between breast cancer patients with progressive disease and objective response to tamoxifen, and additional studies are needed to confirm if the predictive signature might allow identification of individual patients who could benefit from other endocrine therapies.
Journal ArticleDOI
Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.
Jozien Helleman,Maurice P.H.M. Jansen,Kirsten Ruigrok-Ritstier,Iris L. van Staveren,Maxime P. Look,Marion E. Meijer-van Gelder,Anieta M. Sieuwerts,Jan G. M. Klijn,Stefan Sleijfer,John A. Foekens,Els M.J.J. Berns +10 more
TL;DR: FN1, LOX, SPARC, and TIMP3 expression levels are associated with the prognosis of patients with breast cancers, whereas TNC is associated with resistance to tamoxifen therapy.
Journal ArticleDOI
Molecular profiling of platinum resistant ovarian cancer
Jozien Helleman,Maurice P.H.M. Jansen,Paul N. Span,Iris L. van Staveren,Leon F. A. G. Massuger,Marion E. Meijer-van Gelder,Fired C. G. J. Sweep,Patricia C. Ewing,Maria E. L. van der Burg,Gerrit Stoter,Kees Nooter,Els M.J.J. Berns +11 more
TL;DR: The findings of this study are the discovery of a gene signature that classifies the tumours, according to their response, and a 9‐gene set that determines resistance in an independent validation set that outperforms patient and tumour characteristics.
Journal ArticleDOI
HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study
Maurice P.H.M. Jansen,Anieta M. Sieuwerts,Maxime P. Look,Kirsten Ritstier,Marion E. Meijer-van Gelder,Iris L. van Staveren,Jan G. M. Klijn,John A. Foekens,Els M.J.J. Berns +8 more
TL;DR: High HOXB13-to-IL17BR ratio expression levels associate with both tumor aggressiveness and tamoxifen therapy failure, and was significantly associated with DFS and PFS.